Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 7/20 | 0.46 |
| ▸ | OGA | O60502 | 1/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PYGB | P11216 | 1/20 | 0.41 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.38 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.38 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6589158 | 1.00 | LGALS8 (0.46) | LGALS8OGASLC2A1MAPK1PYGB | |
| SCHEMBL9348641 | 1.00 | LGALS8 (0.46) | LGALS8OGASLC2A1MAPK1PYGB | |
| SCHEMBL440314 | 1.00 | LGALS8 (0.46) | LGALS8OGASLC2A1MAPK1PYGB | |
| SCHEMBL4606854 | 1.00 | LGALS8 (0.46) | LGALS8OGASLC2A1MAPK1PYGB | |
| SCHEMBL7927733 | 1.00 | LGALS8 (0.46) | LGALS8OGASLC2A1MAPK1PYGB | |
| SCHEMBL23026283 | 1.00 | LGALS8 (0.46) | LGALS8OGASLC2A1MAPK1PYGB | |
| SCHEMBL7919319 | 1.00 | LGALS8 (0.46) | LGALS8OGASLC2A1MAPK1PYGB | |
| SCHEMBL8614599 | 1.00 | LGALS8 (0.46) | LGALS8OGASLC2A1MAPK1PYGB | |
| SCHEMBL15353147 | 1.00 | LGALS8 (0.46) | LGALS8OGASLC2A1MAPK1PYGB | |
| SCHEMBL8586429 | 1.00 | LGALS8 (0.46) | LGALS8OGASLC2A1MAPK1PYGB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5659022-A | Oligonucleotide-cyclopropapyrroloindole conjugates as sequence specific hybridization and crosslinking agents for nucleic acids | EPOCH PHARMACEUTICALS, INC. (US) | 1997-08-19 | — | — | US | claimed |
| US-4282349-A | Crystalline ribofuranosyl halides and other derivatives and methods for producing same | BOARD OF CONTROL OF MICHIGAN TECHNOLOGICAL UNIVERSITY (US) | 1981-08-04 | — | — | US | claimed |
| US-9334495-B2 | Minor groove binder (MGB)-oligonucleotide miRNA antagonists | ELITECHGROUP B.V. (NL) | 2016-05-10 | — | — | US | disclosed |
| EP-2547769-B1 | MINOR GROOVE BINDER (MGB)-OLIGONUCLEOTIDE MIRNA ANTAGONISTS | ELITECHGROUP B V (NL) | 2016-04-06 | — | — | EP | disclosed |
| US-8980855-B2 | Minor groove binder (MGB)-oligonucleotide miRNA antagonists | ELITECH HOLDING B.V. (NL) | 2015-03-17 | — | — | US | disclosed |
| US-8394813-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120245219-A1 | MINOR GROOVE BINDER (MGB)-OLIGONUCLEOTIDE MIRNA ANTAGONISTS | DHARMACON, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20110172289-A1 | MINOR GROOVE BINDER (MGB)-OLIGONUCLEOTIDE MIRNA ANTAGONISTS | ELITECH HOLDING B.V. | 2011-07-14 | — | — | US | disclosed |
| EP-2316469-A1 | Delivery system and methods for protecting and administering dextroamphetamine | Shire LLC (US) | 2011-05-04 | — | — | EP | disclosed |
| EP-2316468-A1 | Delivery system and methods for protecting and administering dextroamphetamine | Shire LLC (US) | 2011-05-04 | — | — | EP | disclosed |
| EP-2266590-A2 | Active agent delivery sytems and methods for protecting and administering active agents | Shire LLC (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-1999007723-A1 | NUCLEIC ACID UPTAKE AND RELEASE VEHICLE | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 1999-02-18 | — | — | WO | disclosed |
| EP-0743859-A1 | CHIMERIC OLIGONUCLEOSIDE COMPOUNDS | GENTA INCORPORATED (US) | 1996-11-27 | — | — | EP | disclosed |
| EP-0731809-A1 | CHIRALLY ENRICHED SYNTHETIC PHOSPHONATE OLIGOMERS | GENTA INCORPORATED (US) | 1996-09-18 | — | — | EP | disclosed |
| WO-1995013834-A1 | CHIMERIC OLIGONUCLEOSIDE COMPOUNDS | GENTA, INCORPORATED (US) | 1995-05-26 | — | — | WO | disclosed |
| WO-1995014031-A1 | CHIRALLY ENRICHED SYNTHETIC PHOSPHONATE OLIGOMERS | GENTA INCORPORATED (US) | 1995-05-26 | — | — | WO | disclosed |
| US-4914233-A | Synthesis of beta-thymidine | ETHYL CORPORATION (US) | 1990-04-03 | — | — | US | disclosed |
| US-4282349-A | Crystalline ribofuranosyl halides and other derivatives and methods for producing same | BOARD OF CONTROL OF MICHIGAN TECHNOLOGICAL UNIVERSITY (US) | 1981-08-04 | — | — | US | disclosed |
| US-4282349-A | Crystalline ribofuranosyl halides and other derivatives and methods for producing same | BOARD OF CONTROL OF MICHIGAN TECHNOLOGICAL UNIVERSITY (US) | 1981-08-04 | — | — | US | disclosed |
| US-3954752-A | Process for preparing 2',3',5'-tri-0-acetyl-6-azauridine | CESKOSLOVENSKA AKADEMIE VED (CS) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245219-A1 | MINOR GROOVE BINDER (MGB)-OLIGONUCLEOTIDE MIRNA ANTAGONISTS | ZFR, SLIRP, CNBP | LGALS8 748/4885OGA 837/4885SLC2A1 3030/4885 |
| US-20110172289-A1 | MINOR GROOVE BINDER (MGB)-OLIGONUCLEOTIDE MIRNA ANTAGONISTS | ZFR, SLIRP, CNBP | LGALS8 748/4885OGA 837/4885SLC2A1 3030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.